Aion Therapeutic (XCNQ:AION) ROCE % : 0.00% (As of Oct. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Aion Therapeutic ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aion Therapeutic's annualized ROCE % for the quarter that ended in Oct. 2024 was 0.00%.

Aion Therapeutic ROCE % Historical Data

The historical data trend for Aion Therapeutic's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aion Therapeutic ROCE % Chart

Aion Therapeutic Annual Data

Trend

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

ROCE %

Get a 7-Day Free Trial

-10.83

-496.41

Aion Therapeutic Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Aion Therapeutic ROCE % Calculation

Aion Therapeutic's annualized ROCE % for the fiscal year that ended in Apr. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Apr. 2024 )		(A: Apr. 2023 )		(A: Apr. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Apr. 2024 )		(A: Apr. 2023 )		(A: Apr. 2024 )
	=	-6.116	/	( ( (0.211 - 2.936)	+	(0.703 - 4.575) )	/ 2 )
	=	-6.116	/	( (-2.725	+	-3.872)	/ 2 )
	=	-6.116	/	-3.2985
	=	185.42 %

Aion Therapeutic's ROCE % of for the quarter that ended in Oct. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Oct. 2024 )		(Q: Jul. 2024 )		(Q: Oct. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Oct. 2024 )		(Q: Jul. 2024 )		(Q: Oct. 2024 )
	=	-2.072	/	( ( (1.217 - 5.271)	+	(1.542 - 5.649) )	/ 2 )
	=	-2.072	/	( ( -4.054	+	-4.107 )	/ 2 )
	=	-2.072	/	-4.0805
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Oct. 2024) EBIT data.

Aion Therapeutic (XCNQ:AION) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aion Therapeutic ROCE % Related Terms

Thank you for viewing the detailed overview of Aion Therapeutic's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aion Therapeutic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aion Therapeutic Inc (XCNQ:AION) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ANTCF:USA

Address

700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8

Website

https://www.aiontherapeutic.com

Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery. During the year ended the Company had one operating segment, being health and wellness, dedicated to delivering state-of-the-art water filtration solutions. Geographically company earns revenue from USA.

Executives

Ismail Abdul Fattah	Director or Senior Officer of 10% Security Holder
Douglas Craig Wilson	Director or Senior Officer of 10% Security Holder
John Graham Simmonds	Director, Senior Officer

Aion Therapeutic Headlines

No Headlines